Efficacy of vitamin D-3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial

Joost Smolders*, Raymond Hupperts, Frederik Barkhof, Luigi M. E. Grimaldi, Trygve Holmoy, Joep Killestein, Peter Rieckmann, Myriam Schluep, Reinhold Vieth, Ulrike Hostalek, Lizette Ghazi-Visser, Manolo Beelke

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

78 Citations (Web of Science)
Original languageEnglish
Pages (from-to)44-49
JournalJournal of the Neurological Sciences
Issue number1-2
Publication statusPublished - 15 Dec 2011


  • Multiple sclerosis
  • Vitamin D
  • Interferon beta-1a
  • 25-Hydroxyvitamin D
  • 1,25-Dihydroxyvitamin D
  • Clinical trial
  • Biomarker

Cite this